Source Gt Biopharma Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GT Biopharma, Inc Announces 1-for-30 Reverse Stock Split

GT Biopharma, Inc Announces 1-for-30 Reverse Stock Split
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.

United statesCorey davisUniversity of minnesotaComputershare trust companyComputershare incCompany board of directorsSource gt biopharma incCompany special meeting of stockholdersGt biopharma incExchange commissionCompany boardNasdaq capital marketMinimum bid price requirementNasdaq capitalSpecial meetingCommon stock

GT Biopharma, Inc Announces 1-for-30 Reverse Stock Split

GT Biopharma, Inc Announces 1-for-30 Reverse Stock Split
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCorey davisCompany board of directorsUniversity of minnesotaCompany boardComputershare incGt biopharma incGlobe newswire gt biopharma incComputershare trust companyCompany special meeting of stockholdersSource gt biopharma incExchange commissionNasdaq capital marketMinimum bid price requirementNasdaq capitalSpecial meeting

GT Biopharma, Inc Announces 1-for-30 Reverse Stock Split

GT Biopharma, Inc Announces 1-for-30 Reverse Stock Split
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesCorey davisCompany board of directorsGlobe newswire gt biopharma incSource gt biopharma incComputershare trust companyUniversity of minnesotaCompany special meeting of stockholdersExchange commissionCompany boardComputershare incGt biopharma incNasdaq capital marketMinimum bid price requirementNasdaq capitalSpecial meeting

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Presented novel TriKE® pre-clinical data driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment.

Corey davisDavid castanedaJeffrey millerMichael breenPrnewswire gt biopharma incEsmo io congressSource gt biopharma incExchange commissionDevelopment rd expensesOncology esmo io congressEuropean society for medical oncology immunoUniversity of minnesotaGt biopharma incCompany triExecutive chairmanInterim chief executive

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Presented novel TriKE® pre-clinical data driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment.

Corey davisDavid castanedaJeffrey millerMichael breenPrnewswire gt biopharma incEsmo io congressSource gt biopharma incExchange commissionDevelopment rd expensesOncology esmo io congressEuropean society for medical oncology immunoUniversity of minnesotaGt biopharma incCompany triExecutive chairmanInterim chief executive